Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

The antiarrhythmic actions of bisaramil and penticainide result from mixed cardiac ion channel blockade.

Pugsley MK, Hayes ES, Saint DA, Walker MJA.

Biomed Pharmacother. 2018 Dec 27;111:427-435. doi: 10.1016/j.biopha.2018.12.068. [Epub ahead of print]

2.

Molecular charge associated with antiarrhythmic actions in a series of amino-2-cyclohexyl ester derivatives.

Pugsley MK, Yong SL, Goldin AL, Hayes ES, Walker MJA.

Eur J Pharmacol. 2019 Feb 5;844:241-252. doi: 10.1016/j.ejphar.2018.12.025. Epub 2018 Dec 17.

PMID:
30571955
3.

A Proof-of-Concept Evaluation of JTPc and Tp-Tec as Proarrhythmia Biomarkers in Preclinical Species: A Retrospective Analysis by an HESI-Sponsored Consortium.

Boulay E, Abernathy MM, Chu R, Friedrichs GS, Gendron-Parra N, Greiter-Wilke A, Guillon JM, Koerner JE, Menard A, Steidl-Nichols J, Pierson J, Pugsley MK, Rossman EI, Strauss D, Troncy E, Valentin JP, Wisialowski T, Authier S.

Int J Toxicol. 2018 Dec 19:1091581818813601. doi: 10.1177/1091581818813601. [Epub ahead of print]

PMID:
30567462
4.

Corrigendum to An overview of the safety pharmacology society strategic plan [Journal of Pharmacological and Toxicological Methods 93 (2018) 35-45].

Pugsley MK, Authier S, Koerner JE, Redfern WS, Markgraf CG, Brabham T, Correll K, Soloviev MV, Botchway A, Engwall M, Traebert M, Valentin JP, Mow TJ, Greiter-Wilke A, Leishman DJ, Vargas HM.

J Pharmacol Toxicol Methods. 2019 Jan - Feb;95:1. doi: 10.1016/j.vascn.2018.09.003. Epub 2018 Nov 3. No abstract available.

PMID:
30399523
5.

Pharmacological and toxicological activity of RSD921, a novel sodium channel blocker.

Walker MJA, Hayes ES, Saint DA, Adaikan G, Abraham S, Goldin AL, Beatch GN, MacLeod BA, Wall RA, Pugsley MK.

Biomed Pharmacother. 2018 Oct;106:510-522. doi: 10.1016/j.biopha.2018.06.157. Epub 2018 Jul 11.

PMID:
29990839
6.

Safety pharmacology methods and regulatory considerations evolve together.

Pugsley MK, Harter ML, de Korte T, Connaughton C, Authier S, Curtis MJ.

J Pharmacol Toxicol Methods. 2018 Sep - Oct;93:1-6. doi: 10.1016/j.vascn.2018.06.004. Epub 2018 Jun 21. No abstract available.

PMID:
29936032
7.

The evaluation of endpoint variability and implications for study statistical power and sample size in conscious instrumented dogs.

Chiang AY, Guth BD, Pugsley MK, Foley CM, Doyle JM, Engwall MJ, Koerner JE, Parish ST, Dustan Sarazan R.

J Pharmacol Toxicol Methods. 2018 Jul - Aug;92:43-51. doi: 10.1016/j.vascn.2018.02.009. Epub 2018 Mar 2.

8.

An overview of the safety pharmacology society strategic plan.

Pugsley MK, Authier S, Koerner JE, Redfern WS, Markgraf CG, Brabham T, Correll K, Soloviev MV, Botchway A, Engwall M, Traebert M, Valentin JP, Mow TJ, Greiter-Wilke A, Leishman DJ, Vargas HM.

J Pharmacol Toxicol Methods. 2018 Sep - Oct;93:35-45. doi: 10.1016/j.vascn.2018.01.001. Epub 2018 Jan 9. Review. Erratum in: J Pharmacol Toxicol Methods. 2019 Jan - Feb;95:1.

PMID:
29330132
9.

The Safety Pharmacology Society salary survey.

Pugsley MK, Authier S, Brabham T, Soloviev M, Markgraf CG, Correll K, Traebert M, Greiter-Wilke A, Valentin JP, Vargas H, Botchway A, Leishman DJ, Curtis MJ.

J Pharmacol Toxicol Methods. 2017 Nov;88(Pt 1):85-91. doi: 10.1016/j.vascn.2017.08.002. Epub 2017 Aug 7.

PMID:
28797763
10.

Safety pharmacology methods and models in an evolving regulatory environment.

Pugsley MK, de Korte T, Authier S, Huang H, Accardi MV, Curtis MJ.

J Pharmacol Toxicol Methods. 2017 Sep;87:1-6. doi: 10.1016/j.vascn.2017.04.012. Epub 2017 Apr 29.

PMID:
28461240
11.

Cardiac contractility: Correction strategies applied to telemetry data from a HESI-sponsored consortium.

Boulay E, Pugsley MK, Jacquemet V, Vinet A, Accardi MV, Soloviev M, Troncy E, Doyle JM, Pierson JB, Authier S.

J Pharmacol Toxicol Methods. 2017 Sep;87:38-47. doi: 10.1016/j.vascn.2017.04.009. Epub 2017 Apr 21.

12.

An overview of the safety pharmacology career of Dr. C.R. Hassler.

Hawk MA, Pugsley MK, Vinci T, Wallery J, Hassler CR, Hamlin RL.

J Pharmacol Toxicol Methods. 2017 Sep;87:7-10. doi: 10.1016/j.vascn.2017.04.005. Epub 2017 Apr 17.

PMID:
28428100
13.

Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.

Huang H, Pugsley MK, Fermini B, Curtis MJ, Koerner J, Accardi M, Authier S.

J Pharmacol Toxicol Methods. 2017 Sep;87:11-23. doi: 10.1016/j.vascn.2017.04.002. Epub 2017 Apr 11. Review.

14.

Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice.

Authier S, Pugsley MK, Koerner JE, Fermini B, Redfern WS, Valentin JP, Vargas HM, Leishman DJ, Correll K, Curtis MJ.

J Pharmacol Toxicol Methods. 2017 Jul;86:34-43. doi: 10.1016/j.vascn.2017.02.021. Epub 2017 Feb 20.

15.

GLP in safety pharmacology studies: Report card after 15years.

Guth BD, Pugsley MK.

J Pharmacol Toxicol Methods. 2017 Sep;87:24-26. doi: 10.1016/j.vascn.2017.02.016. Epub 2017 Feb 10. No abstract available.

PMID:
28192184
16.

An evaluation of the utility of LVdP/dt40, QA interval, LVdP/dtmin and Tau as indicators of drug-induced changes in contractility and lusitropy in dogs.

Pugsley MK, Guth B, Chiang AY, Doyle JM, Engwall M, Guillon JM, Hoffmann PK, Koerner JE, Mittelstadt SW, Pierson JB, Rossman EI, Sarazan DR, Parish ST.

J Pharmacol Toxicol Methods. 2017 May - Jun;85:1-21. doi: 10.1016/j.vascn.2017.01.002. Epub 2017 Jan 5.

17.

The northeast regional SPS meeting update: Safety pharmacology innovations and applications.

Pannirselvam M, Brabham T, Botchway AW, Hodges DB, Traebert M, Pugsley MK.

J Pharmacol Toxicol Methods. 2017 May - Jun;85:82-86. doi: 10.1016/j.vascn.2016.11.005. Epub 2016 Nov 30. Review.

PMID:
27913272
18.

Citrulline as a Biomarker for Gastrointestinal-Acute Radiation Syndrome: Species Differences and Experimental Condition Effects.

Bujold K, Hauer-Jensen M, Donini O, Rumage A, Hartman D, Hendrickson HP, Stamatopoulos J, Naraghi H, Pouliot M, Ascah A, Sebastian M, Pugsley MK, Wong K, Authier S.

Radiat Res. 2016 Jul;186(1):71-8. doi: 10.1667/RR14305.1. Epub 2016 Jun 28.

19.

Recalibration of nonclinical safety pharmacology assessment to anticipate evolving regulatory expectations.

Pugsley MK, Authier S, Hayes ES, Hamlin RL, Accardi MV, Curtis MJ.

J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:1-8. doi: 10.1016/j.vascn.2016.06.005. Epub 2016 Jun 22.

PMID:
27343819
20.

Safety pharmacology investigations on the nervous system: An industry survey.

Authier S, Arezzo J, Delatte MS, Kallman MJ, Markgraf C, Paquette D, Pugsley MK, Ratcliffe S, Redfern WS, Stevens J, Valentin JP, Vargas HM, Curtis MJ.

J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:37-46. doi: 10.1016/j.vascn.2016.06.001. Epub 2016 Jun 2.

PMID:
27263834
21.

The emerging role of in vitro electrophysiological methods in CNS safety pharmacology.

Accardi MV, Pugsley MK, Forster R, Troncy E, Huang H, Authier S.

J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:47-59. doi: 10.1016/j.vascn.2016.03.008. Epub 2016 Apr 4. Review.

22.

Charge is an important determinant of hemodynamic and adverse cardiovascular effects of cationic drugs.

Pugsley MK, Authier S, Curtis MJ.

Pharmacol Res. 2015 Dec;102:46-52. doi: 10.1016/j.phrs.2015.09.008. Epub 2015 Sep 11.

PMID:
26368292
23.

Preface.

Pugsley MK.

Handb Exp Pharmacol. 2015;229:v. No abstract available.

PMID:
26307815
24.

Haemodynamic Assessment in Safety Pharmacology.

Authier S, Pugsley MK, Curtis MJ.

Handb Exp Pharmacol. 2015;229:221-41. doi: 10.1007/978-3-662-46943-9_9.

PMID:
26091642
25.

Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.

Pugsley MK, Curtis MJ, Hayes ES.

Handb Exp Pharmacol. 2015;229:149-203. doi: 10.1007/978-3-662-46943-9_7. Review.

PMID:
26091640
26.

An examination of the cardiac actions of PD117,302, a κ-opioid receptor agonist.

Pugsley MK, Saint DA, Hayes ES, Abraham S, Walker MJ.

Eur J Pharmacol. 2015 Aug 15;761:330-40. doi: 10.1016/j.ejphar.2015.06.018. Epub 2015 Jun 15.

PMID:
26086860
27.

The shifting landscape of safety pharmacology in 2015.

Pugsley MK, Authier S, Stonerook M, Curtis MJ.

J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:5-9. doi: 10.1016/j.vascn.2015.05.013. Epub 2015 Jun 6.

PMID:
26055120
28.

Evaluation of drug-induced QT interval prolongation in animal and human studies: a literature review of concordance.

Vargas HM, Bass AS, Koerner J, Matis-Mitchell S, Pugsley MK, Skinner M, Burnham M, Bridgland-Taylor M, Pettit S, Valentin JP.

Br J Pharmacol. 2015 Aug;172(16):4002-11. doi: 10.1111/bph.13207. Epub 2015 Jul 14. Review.

29.

The Diplomate in Safety Pharmacology (DSP) certification scheme.

Authier S, Curtis MJ, Soloviev M, Redfern WS, Kallman MJ, Hamlin RL, Leishman DJ, Valentin JP, Koerner JE, Vargas HM, Botchway A, Correll K, Pugsley MK.

J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:1-4. doi: 10.1016/j.vascn.2015.04.008. Epub 2015 May 8.

PMID:
25959882
30.

Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates.

Polak S, Pugsley MK, Stockbridge N, Garnett C, Wiśniowska B.

AAPS J. 2015 Jul;17(4):1025-32. doi: 10.1208/s12248-015-9773-1. Epub 2015 May 5. No abstract available.

31.

Ventricular arrhythmia incidence in the rat is reduced by naloxone.

Pugsley MK, Hayes ES, Wang WQ, Walker MJ.

Pharmacol Res. 2015 Jul;97:64-9. doi: 10.1016/j.phrs.2015.04.011. Epub 2015 Apr 25.

PMID:
25920674
32.

The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESI-sponsored consortium.

Guth BD, Chiang AY, Doyle J, Engwall MJ, Guillon JM, Hoffmann P, Koerner J, Mittelstadt S, Ottinger S, Pierson JB, Pugsley MK, Rossman EI, Walisser J, Sarazan RD.

J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:70-90. doi: 10.1016/j.vascn.2015.02.002. Epub 2015 Apr 3.

33.

Reprint of "Safety pharmacology in 2014: New focus on non-cardiac methods and models".

Pugsley MK, Dalton JA, Authier S, Curtis MJ.

J Pharmacol Toxicol Methods. 2014 Nov-Dec;70(3):199-203. doi: 10.1016/j.vascn.2014.10.002. Epub 2014 Oct 25.

PMID:
25467811
34.

Safety pharmacology in 2014: new focus on non-cardiac methods and models.

Pugsley MK, Dalton JA, Authier S, Curtis MJ.

J Pharmacol Toxicol Methods. 2014 Sep-Oct;70(2):170-4. doi: 10.1016/j.vascn.2014.08.004. Epub 2014 Aug 14.

PMID:
25128820
35.

Safety pharmacology investigations in toxicology studies: an industry survey.

Authier S, Vargas HM, Curtis MJ, Holbrook M, Pugsley MK.

J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):44-51. doi: 10.1016/j.vascn.2013.05.002. Epub 2013 May 14.

PMID:
23685201
36.

The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias.

Curtis MJ, Hancox JC, Farkas A, Wainwright CL, Stables CL, Saint DA, Clements-Jewery H, Lambiase PD, Billman GE, Janse MJ, Pugsley MK, Ng GA, Roden DM, Camm AJ, Walker MJ.

Pharmacol Ther. 2013 Aug;139(2):213-48. doi: 10.1016/j.pharmthera.2013.04.008. Epub 2013 Apr 12.

PMID:
23588158
37.

Attrition in the drug discovery process: lessons to be learned from the safety pharmacology paradigm.

Curtis MJ, Pugsley MK.

Expert Rev Clin Pharmacol. 2012 May;5(3):237-40. doi: 10.1586/ecp.12.22. No abstract available.

PMID:
22697586
38.

Methodological innovations expand the safety pharmacology horizon.

Pugsley MK, Curtis MJ.

J Pharmacol Toxicol Methods. 2012 Sep;66(2):59-62. doi: 10.1016/j.vascn.2012.05.004. Epub 2012 May 20.

PMID:
22617368
39.

Cardiorespiratory safety evaluation in non-human primates.

Ingram-Ross JL, Curran AK, Miyamoto M, Sheehan J, Thomas G, Verbeeck J, de Waal EJ, Verstynen B, Pugsley MK.

J Pharmacol Toxicol Methods. 2012 Sep;66(2):114-24. doi: 10.1016/j.vascn.2012.04.002. Epub 2012 Apr 12.

PMID:
22521338
40.

Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2.

Eichenbaum G, Pugsley MK, Gallacher DJ, Towart R, McIntyre G, Shukla U, Davenport JM, Lu HR, Rohrbacher J, Hillsamer V.

Br J Pharmacol. 2012 Jul;166(5):1694-707. doi: 10.1111/j.1476-5381.2012.01874.x.

41.

Innovation in safety pharmacology testing.

Pugsley MK, Towart R, Authier S, Gallacher DJ, Curtis MJ.

J Pharmacol Toxicol Methods. 2011 Jul-Aug;64(1):1-6. doi: 10.1016/j.vascn.2011.05.005. Epub 2011 May 27.

PMID:
21640842
42.

The 'overly-sensitive' heart: sodium channel block and QRS interval prolongation.

Gintant GA, Gallacher DJ, Pugsley MK.

Br J Pharmacol. 2011 Sep;164(2):254-9. doi: 10.1111/j.1476-5381.2011.01433.x.

43.

An overview of colorimetric assay methods used to assess survival or proliferation of mammalian cells.

Vega-Avila E, Pugsley MK.

Proc West Pharmacol Soc. 2011;54:10-4. Review.

PMID:
22423572
44.

Electrocardiographic assessment for therapeutic proteins--scientific discussion.

Rodriguez I, Erdman A, Padhi D, Garnett CE, Zhao H, Targum SL, Balakrishnan S, Strnadova C, Viner N, Geiger MJ, Newton-Cheh C, Litwin J, Pugsley MK, Sager PT, Krucoff MW, Finkle JK.

Am Heart J. 2010 Oct;160(4):627-34. doi: 10.1016/j.ahj.2010.07.001. Review.

PMID:
20934555
45.

Non-clinical models: validation, study design and statistical consideration in safety pharmacology.

Pugsley MK, Towart R, Authier S, Gallacher DJ, Curtis MJ.

J Pharmacol Toxicol Methods. 2010 Jul-Aug;62(1):1-3. doi: 10.1016/j.vascn.2010.06.003. Epub 2010 Jun 22.

PMID:
20601022
46.

Arrhythmogenic liability screening in cardiovascular safety pharmacology: commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies.

Authier S, Pugsley MK, Troncy E, Curtis MJ.

J Pharmacol Toxicol Methods. 2010 Sep-Oct;62(2):83-8. doi: 10.1016/j.vascn.2010.06.005. Epub 2010 Jun 19. Review.

PMID:
20601020
47.

The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?

Lee N, Authier S, Pugsley MK, Curtis MJ.

Toxicol Appl Pharmacol. 2010 Mar 1;243(2):146-53. doi: 10.1016/j.taap.2009.12.002. Epub 2009 Dec 18. Review.

PMID:
20005885
48.

Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?

Pugsley MK, Authier S, Towart R, Gallacher DJ, Curtis MJ.

J Pharmacol Toxicol Methods. 2009 Jul-Aug;60(1):24-7. doi: 10.1016/j.vascn.2009.07.001. Epub 2009 Jul 15.

PMID:
19616107
49.

The non-GLP toleration/dose range finding study: design and methodology used in an early toxicology screening program.

Herlich JA, Taggart P, Proctor J, Stahle P, Colis R, Hall L, Pugsley MK.

Proc West Pharmacol Soc. 2009;52:94-8.

PMID:
22128433
50.

Methods in safety pharmacology in focus.

Pugsley MK, Gallacher DJ, Towart R, Authier S, Curtis MJ.

J Pharmacol Toxicol Methods. 2008 Sep-Oct;58(2):69-71. doi: 10.1016/j.vascn.2008.07.002. Epub 2008 Jul 22.

PMID:
18707009

Supplemental Content

Loading ...
Support Center